Oral Transmucosal Drugs Market

Oral Transmucosal Drugs Market (Type: Tablets, Buccal Films, Liquid & Spray, Gels, and Others; Route of Penetration: Sublingual Mucosa, Buccal Mucosa, Gingival Tissues, and Palatal Tissues; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies; and Indication: Cardiovascular Disorders, Acute Pain Management, Sedation, Erectile Dysfunction, Diabetes, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Oral Transmucosal Drugs May Prevent Rapid Deterioration of COVID-19 Patients

The COVID-19 pandemic has led to a need for alternative routes of drug administration for end of life and palliative care. This has brought stakeholders in the oral transmucosal drugs market under scrutiny, especially in community settings. Popular transmucosal routes such as buccal, intranasal, sublingual, and rectal are being publicized. This has led to the scope of non-invasive routes for systematic drug delivery with the potential for self-administration or administration by family caregivers.

Companies in the oral transmucosal drugs market are capitalizing on the ability to offer rapid onset of action with reduced first-pass metabolism. Oral transmucosal drugs are being increasingly used in palliative and end of life care to provide fast relief of symptoms. Such findings are benefitting healthcare providers during the coronavirus outbreak, since the health of some patients tends to deteriorate rapidly in certain cases.

oral transmucosal drugs market infographic

To know the scope of our report Get a Sample on Oral Transmucosal Drugs Market

Mucoadhesive Polymers Hold High Potential to Improve Drug Delivery in Patients

The successful delivery of drugs across the oral mucosa represents a continuing challenge as well as an opportunity for stakeholders in the oral transmucosal drugs market. This explains why the market is estimated to clock a favorable CAGR of ~6% during the forecast period. Hence, companies are expected to collaborate with researchers, scientists, and biologists to increase R&D in novel mucoadhesive polymers. They are increasing efforts to design improved drug delivery systems that achieve delivery through the different mucosa.

Transmucosal drug delivery systems are gaining increased popularity, as mucous membranes are relatively permeable, which facilitate the rapid uptake of a drug into the systemic circulation. Companies are boosting their production capabilities in mucoadhesive polymers under different dosage forms such as tablets, films, semisolids, and powders.

Get a glimpse of the in-depth analysis through our Report Brochure

Novel Permeation Enhancers Enable Active Ingredients to Penetrate Mucosa

Despite the number of advantages linked with transmucosal drug delivery, the medicines delivered as buccal or sublingual formulations remain relatively low. Aquestive Therapeutics - a specialty pharmaceutical company is finding opportunity in this challenge, and increasing its focus on developing novel permeation enhancers, stabilizers, and polymer blends that can boost the ability of active ingredients to penetrate the mucosa. Such innovations explain why the oral transmucosal drugs market is expected to reach US$ 27 Bn by 2031.

Proprietary compositional profiles of oral films are being tailored to the buccal or sublingual microenvironment in order to achieve a desired rate of absorption. This is evident since buccal films are likely to dominate the second-highest revenue among all drug types in the oral transmucosal drugs market.

Buccal Films Preferred Over Buccal Tablets

Extensive research is being carried out on the design and development of innovative drug delivery systems to improve their efficacy, safety, and patient compliance. Buccal films are the most recently developed dosage form for buccal administration. Companies in the oral transmucosal drugs market are capitalizing on this opportunity, since buccal films are gaining importance as efficacious and novel drug delivery systems that are cost-efficient and enable good patient compliance.

As buccal films are implied for attachment to the buccal mucosa, they can be formulated to exhibit local as well as systemic action. Pharmaceutical companies in the oral transmucosal drugs market are bolstering their output capacities in buccal films, since they are being preferred over buccal tablets, owing to the former’s flexibility and comfort. It has been found that buccal films have direct access to the systemic circulation through the jugular vein, which bypasses the drug from the hepatic first pass metabolism leading to the high bioavailability.

Precision Dosing Capacities of Oral Thin Films Grabbing Attention of Stakeholders

Oral thin films are storming the oral transmucosal drugs market. CURE Pharmaceutical Holding Corp. is gaining popularity for its flagship technology CUREfilm® that is a thin oral film platform, which optimizes the absorption and metabolism of therapeutic actives. Companies are taking cues from such innovations, and focusing on the oral soluble film technology that offers a versatile dose form and allows manufacturers to create proprietary products with optimal release profiles. This ensures better patient outcomes with oral thin films and enhanced consumer experiences.

Companies in the oral transmucosal drugs market are increasing their production of oral thin films, attributed to ease of use, high load, precision dosing, and fast acting capacities.

Mucoadhesion Helps Prolong Residence Time of Drugs on Mucus

The advanced materials for drug delivery across mucosal barriers are being developed by companies in the oral transmucosal drugs market. Mucus is a viscoelastic gel that traps pathogens and other foreign particles to limit their penetration into the underlying epithelium. On the other hand, dosage forms containing particle-based drug delivery systems are trapped in mucosal layers and tend to be removed by mucus turnover. This has driven companies in the oral transmucosal drugs market to increase their R&D activities in mucoadhesion, which helps to avoid premature wash-off and prolongs the residence time of drugs on mucus.

Mucoadhesion helps in mucus penetration, which is essential for molecules to access the underlying epithelial tissues. As such, various strategies are being investigated to achieve mucoadhesion and mucus penetration of drug carriers.

Micro, Nanoscale Drug Carriers Enable Sustainable Release of Drugs at Target Sites

The pharmaceutical companies in the oral transmucosal drugs market are acquiring a strong research base in micro and nanoscale technologies. The smart and controlled oral drug deliveries are predicted to bypass the physiological barriers that limit the oral delivery of hydrophilic therapeutics. Micro and nanoscale technologies are known for their unprecedented ability to create, control, and measure micro- or nano-environments that have found increased number of applications in biology and medicine.

Micro and nanoscale drug carriers such as bioadhesives, microparticles and nano-particles are being developed by pharmaceutical companies. The integration of bioadhesive properties improves the oral drug delivery of fabricated carriers. One of the key purpose of utilizing bio-adhesive materials is to delay the transit of cargos to enable the sustainable release of drugs at target sites. This helps to prolong the residence time in order to enhance the drug absorption process.

oral transmucosal drugs market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Though oral transmucosal drugs have the potential for self-administration in COVID-19 patients, it is met with challenges such as relatively small surface area for effective drug absorption. Companies are increasing their R&D activities to better the drug administration in coronavirus patients, since even after vaccination there is a high risk of reinfection in patients.

The oral administration is one of the most important pillars of the pharmaceutical industry. However, it is still challenging to administer hydrophilic therapeutics by the oral route. Hence, companies in the oral transmucosal drugs market should mainly focus on the design of carriers with bio-adhesive properties for oral transmucosal drugs and the administration of hydrophilic therapeutics.

Oral Transmucosal Drugs Market: Overview

  • This report analyzes the current scenario and future prospects of the global oral transmucosal drugs market. Rise in adoption of oral transmucosal drugs among the geriatric population and surge in prevalence of dysphagia are the key factors projected to drive the global oral transmucosal drugs market during the forecast period.
  • The report includes an elaborate executive summary, which provides a snapshot of various segments of the global oral transmucosal drugs market. It also provides information and data analysis of the oral transmucosal drugs market about segments based on type, route of penetration, distribution channel, indication, and region.
  • The overview section of the report provides a detailed qualitative analysis of drivers, restraints, and opportunities that impact the global oral transmucosal drugs market
  • The report includes company profiles, which provide information about their business, product portfolios, and competitive landscape in the global oral transmucosal drugs market
  • The report on the oral transmucosal drugs market offers market attractiveness analysis of regions and segments
  • The last section of the report comprises quantitative and qualitative analyses on market share/position of key players operating in the global oral transmucosal drugs market. It analyzes key competitive strategies adopted by major industry players, thereby presenting a thorough understanding of the competitive scenario in the global oral transmucosal drugs market.

Oral Transmucosal Drugs market: Key Segments

  • In terms of type, the global oral transmucosal drugs market has been classified into tablets, buccal films, liquid & spray, gels, and others. The tablets segment dominated the global market in 2020, owing to the advantages offered by oral transmucosal tablets. These include improved stability, cost-effectiveness, rapid dissolution and absorption of drug, low sensitivity to environmental condition, and ease of administration.
  • The tablets segment has been split into sublingual tablets, buccal tablets, lozenges & troches, and others
  • Based on route of penetration, the global oral transmucosal drugs market has been categorized into sublingual mucosa, buccal mucosa, gingival tissues, and palatal tissues. The buccal mucosa segment dominated the global market in 2020.
  • In terms of distribution channel, the global oral transmucosal drugs market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The online pharmacies segment is expected to expand at a high CAGR from 2021 to 2031. Detailed product information available on the site and rise in convenience in choosing drug from websites are likely to augment the segment.
  • Based on indication, the global oral transmucosal drugs market has been divided into cardiovascular disorders, acute pain management, sedation, erectile dysfunction, diabetes, and others. The diabetes segment is projected to expand at a high CAGR from 2021 to 2031, owing to rise in prevalence of diabetes worldwide.
  • Market size and forecast for each of these segments have been provided from 2017 to 2031. The CAGR of respective segment has also been provided from 2021 to 2031, considering 2020 as the base year.

Oral Transmucosal Drugs Market: Regional Outlook

  • In terms of region, the global oral transmucosal drugs market has been segmented into North America (the U.S. and Canada), Europe (the U.K., Germany, Spain, Italy, France, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa). Each region considered in the market has been divided into countries/sub-regions.
  • The oral transmucosal drugs market report provides size and forecast for each region and country/sub-region from 2017 to 2031. The CAGR for each of these regions and countries has also been provided for the forecast period from 2021 to 2031. The oral transmucosal drugs market study also covers the competitive scenario in these regions.

Companies Covered in Oral Transmucosal Drugs Market Report

  • Key players in the global oral transmucosal drugs market have been profiled based on attributes such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies
  • Major companies profiled in the oral transmucosal drugs market report are
    • LTS Lohmann Therapie-Systeme AG
    • Soligenix
    • ZIM Laboratories Limited
    • Access Pharmaceutical Inc.
    • C.L Pharm
    • Seoul Pharmaceuticals
    • Cure Pharmaceutical
    • Aquestive Therapeutics, Inc.
    • Solvay S.A.
    • NAL Pharma
    • IntelGenx Corp.
    • Izun Pharmaceuticals
    • Eisai Co., Ltd.
    • AstraZeneca
    • Otsuka Pharmaceutical Co., Ltd.
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc
    • Mylan N.V.
    • Bristol-Myers Squibb Company

Oral Transmucosal Drugs Market – Segmentation

Type
  • Tablets
    • Sublingual Tablets
    • Buccal Tablets
    • Lozenges & Troches
    • Others
  • Buccal Films
  • Liquid & Spray
    • Aqueous Solutions
    • Suspensions
  • Gels
  • Others
Route of Penetration
  • Sublingual Mucosa
  • Buccal Mucosa
  • Gingival Tissues
  • Palatal Tissues
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Indication
  • Cardiovascular Disorders
  • Acute Pain Management
  • Sedation
  • Erectile Dysfunction
  • Diabetes
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of oral transmucosal drugs market?

Oral transmucosal drugs market is expected to reach US$ 27 billion by 2031

What is the anticipated CAGR of the oral transmucosal drugs market in the forecast period?

Oral transmucosal drugs market is anticipated to expand at a CAGR of 6% to 2021-2031

What are the key driving factors for the growth of the oral transmucosal drugs market?

Oral transmucosal drugs market is driven by rise in prevalence of neurological disorders and chronic diseases, increase in geriatric population, and adoption of novel drug delivery systems

Which is the rising prominent segment in the oral transmucosal drugs market?

The buccal mucosa segment held major share of the global oral transmucosal drugs market

Who are the key players in the global oral transmucosal drugs market?

Top key players in oral transmucosal drugs market are LTS Lohmann Therapie-Systeme AG, Soligenix, ZIM Laboratories Limited, Access Pharmaceutical Inc., C.L Pharm, Seoul Pharmaceuticals, Cure Pharmaceutical, Aquestive Therapeutics, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Oral Transmucosal Drugs Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Type Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Oral Transmucosal Drugs Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Key Mergers & Acquisitions 

        5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

        5.3. Top 3 players operating in the market space

        5.4. Clinical Trials & Pipeline Analysis

        5.5. Oral Transmucosal Drugs Market SWOT Analysis

    6. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Type, 2017–2031

            6.3.1. Tablets

                6.3.1.1. Sublingual Tablets 

                6.3.1.2. Buccal Tablets 

                6.3.1.3. Lozenges & Troches

                6.3.1.4. Others

            6.3.2. Buccal Films 

            6.3.3. Liquid & Spray

                6.3.3.1. Aqueous Solutions

                6.3.3.2. Suspensions 

            6.3.4. Gels

            6.3.5. Others

        6.4. Market Attractiveness Analysis, by Type 

    7. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Route of Penetration

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Route of Penetration, 2017–2031

            7.3.1. Sublingual Mucosa

            7.3.2. Buccal Mucosa

            7.3.3. Gingival Tissues

            7.3.4. Palatal Tissues

        7.4. Market Attractiveness Analysis, by Route of Penetration 

    8. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Distribution Channel, 2017–2031

            8.3.1. Hospital Pharmacies

            8.3.2. Retail Pharmacies

            8.3.3. Online Pharmacies

        8.4. Market Attractiveness Analysis, by Distribution Channel 

    9. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Indication

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast, by Indication, 2017–2031

            9.3.1. Cardiovascular Disorders

            9.3.2. Acute Pain Management

            9.3.3. Sedation

            9.3.4. Erectile Dysfunction

            9.3.5. Diabetes

            9.3.6. Others

        9.4. Market Attractiveness Analysis, by Indication 

    10. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Region

        10.1. Key Findings

        10.2. Market Value Forecast, by Region

            10.2.1. North America 

            10.2.2. Europe 

            10.2.3. Asia Pacific 

            10.2.4. South Korea 

            10.2.5. Latin America 

            10.2.6. Middle East & Africa 

        10.3. Market Attractiveness Analysis, by Country/Region

    11. North America Oral Transmucosal Drugs Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Type, 2017–2031

            11.2.1. Tablets

                11.2.1.1. Sublingual Tablets 

                11.2.1.2. Buccal Tablets 

                11.2.1.3. Lozenges & Troches

                11.2.1.4. Others

            11.2.2. Buccal Films 

            11.2.3. Liquid & Spray

                11.2.3.1. Aqueous Solutions

                11.2.3.2. Suspensions 

            11.2.4. Gels

            11.2.5. Others

        11.3. Market Value Forecast, by Route of Penetration, 2017–2031

            11.3.1. Sublingual Mucosa

            11.3.2. Buccal Mucosa

            11.3.3. Gingival Tissues

            11.3.4. Palatal Tissues

        11.4. Market Value Forecast, by Distribution Channel, 2017–2031

            11.4.1. Hospital Pharmacies

            11.4.2. Retail Pharmacies

            11.4.3. Online Pharmacies

        11.5. Market Value Forecast, by Indication, 2017–2031

            11.5.1. Cardiovascular Disorders

            11.5.2. Acute Pain Management

            11.5.3. Sedation

            11.5.4. Erectile Dysfunction

            11.5.5. Diabetes

            11.5.6. Others

        11.6. Market Value Forecast, by Country, 2017–2031

            11.6.1. U.S. 

            11.6.2. Canada 

        11.7. Market Attractiveness Analysis 

            11.7.1. By Type 

            11.7.2. By Route of Penetration 

            11.7.3. By Distribution Channel 

            11.7.4. By Indication 

            11.7.5. By Country

    12. Europe Oral Transmucosal Drugs Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Type, 2017–2031

            12.2.1. Tablets

                12.2.1.1. Sublingual Tablets 

                12.2.1.2. Buccal Tablets 

                12.2.1.3. Lozenges & Troches

                12.2.1.4. Others

            12.2.2. Buccal Films 

            12.2.3. Liquid & Spray

                12.2.3.1. Aqueous Solutions

                12.2.3.2. Suspensions 

            12.2.4. Gels

            12.2.5. Others

        12.3. Market Value Forecast, by Route of Penetration, 2017–2031

            12.3.1. Sublingual Mucosa

            12.3.2. Buccal Mucosa

            12.3.3. Gingival Tissues

            12.3.4. Palatal Tissues

        12.4. Market Value Forecast, by Distribution Channel, 2017–2031

            12.4.1. Hospital Pharmacies

            12.4.2. Retail Pharmacies

            12.4.3. Online Pharmacies

        12.5. Market Value Forecast, by Indication, 2017–2031

            12.5.1. Cardiovascular Disorders

            12.5.2. Acute Pain Management

            12.5.3. Sedation

            12.5.4. Erectile Dysfunction

            12.5.5. Diabetes

            12.5.6. Others

        12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.6.1. Germany 

            12.6.2. U.K. 

            12.6.3. France 

            12.6.4. Italy 

            12.6.5. Spain 

            12.6.6. Rest of Europe 

        12.7. Market Attractiveness Analysis 

            12.7.1. By Type 

            12.7.2. By Route of Penetration 

            12.7.3. By Distribution Channel 

            12.7.4. By Indication 

            12.7.5. By Country/Sub-region

    13. Asia Pacific Oral Transmucosal Drugs Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Type, 2017–2031

            13.2.1. Tablets

                13.2.1.1. Sublingual Tablets 

                13.2.1.2. Buccal Tablets 

                13.2.1.3. Lozenges & Troches

                13.2.1.4. Others

            13.2.2. Buccal Films 

            13.2.3. Liquid & Spray

                13.2.3.1. Aqueous Solutions

                13.2.3.2. Suspensions 

            13.2.4. Gels

            13.2.5. Others

        13.3. Market Value Forecast, by Route of Penetration, 2017–2031

            13.3.1. Sublingual Mucosa

            13.3.2. Buccal Mucosa

            13.3.3. Gingival Tissues

            13.3.4. Palatal Tissues

        13.4. Market Value Forecast, by Distribution Channel, 2017–2031

            13.4.1. Hospital Pharmacies

            13.4.2. Retail Pharmacies

            13.4.3. Online Pharmacies

        13.5. Market Value Forecast, by Indication, 2017–2031

            13.5.1. Cardiovascular Disorders

            13.5.2. Acute Pain Management

            13.5.3. Sedation

            13.5.4. Erectile Dysfunction

            13.5.5. Diabetes

            13.5.6. Others

        13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.6.1. Japan 

            13.6.2. China 

            13.6.3. India 

            13.6.4. Australia & New Zealand 

            13.6.5. South Korea

            13.6.6. Rest of Asia Pacific 

        13.7. Market Attractiveness Analysis 

            13.7.1. By Type 

            13.7.2. By Route of Penetration 

            13.7.3. By Distribution Channel 

            13.7.4. By Indication 

            13.7.5. By Country/Sub-region

    14. Latin America Oral Transmucosal Drugs Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Type, 2017–2031

            14.2.1. Tablets

                14.2.1.1. Sublingual Tablets 

                14.2.1.2. Buccal Tablets 

                14.2.1.3. Lozenges & Troches

                14.2.1.4. Others

            14.2.2. Buccal Films 

            14.2.3. Liquid & Spray

                14.2.3.1. Aqueous Solutions

                14.2.3.2. Suspensions 

            14.2.4. Gels

            14.2.5. Others

        14.3. Market Value Forecast, by Route of Penetration, 2017–2031

            14.3.1. Sublingual Mucosa

            14.3.2. Buccal Mucosa

            14.3.3. Gingival Tissues

            14.3.4. Palatal Tissues

        14.4. Market Value Forecast, by Distribution Channel, 2017–2031

            14.4.1. Hospital Pharmacies

            14.4.2. Retail Pharmacies

            14.4.3. Online Pharmacies

        14.5. Market Value Forecast, by Indication, 2017–2031

            14.5.1. Cardiovascular Disorders

            14.5.2. Acute Pain Management

            14.5.3. Sedation

            14.5.4. Erectile Dysfunction

            14.5.5. Diabetes

            14.5.6. Others

        14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.6.1. Brazil 

            14.6.2. Mexico 

            14.6.3. Rest of Latin America 

        14.7. Market Attractiveness Analysis 

            14.7.1. By Type 

            14.7.2. By Route of Penetration 

            14.7.3. By Distribution Channel 

            14.7.4. By Indication 

            14.7.5. By Country/Sub-region

    15. Middle East & Africa Oral Transmucosal Drugs Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Type, 2017–2031

            15.2.1. Tablets

                15.2.1.1. Sublingual Tablets 

                15.2.1.2. Buccal Tablets 

                15.2.1.3. Lozenges & Troches

                15.2.1.4. Others

            15.2.2. Buccal Films 

            15.2.3. Liquid & Spray

                15.2.3.1. Aqueous Solutions

                15.2.3.2. Suspensions 

            15.2.4. Gels

            15.2.5. Others

        15.3. Market Value Forecast, by Route of Penetration, 2017–2031

            15.3.1. Sublingual Mucosa

            15.3.2. Buccal Mucosa

            15.3.3. Gingival Tissues

            15.3.4. Palatal Tissues

        15.4. Market Value Forecast, by Distribution Channel, 2017–2031

            15.4.1. Hospital Pharmacies

            15.4.2. Retail Pharmacies

            15.4.3. Online Pharmacies

        15.5. Market Value Forecast, by Indication, 2017–2031

            15.5.1. Cardiovascular Disorders

            15.5.2. Acute Pain Management

            15.5.3. Sedation

            15.5.4. Erectile Dysfunction

            15.5.5. Diabetes

            15.5.6. Others

        15.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            15.6.1. GCC Countries 

            15.6.2. South Africa 

            15.6.3. Rest of Middle East & Africa 

        15.7. Market Attractiveness Analysis 

            15.7.1. By Type 

            15.7.2. By Route of Penetration 

            15.7.3. By Distribution Channel 

            15.7.4. By Indication 

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Share Analysis, by Company, 2020

        16.2. Company Profiles

            16.2.1. LTS Lohmann Therapie-Systeme AG

                16.2.1.1. Company Overview

                16.2.1.2. Company Financials

                16.2.1.3. Growth Strategies

                16.2.1.4. SWOT Analysis

            16.2.2. Soligenix

                16.2.2.1. Company Overview

                16.2.2.2. Company Financials16.

                16.2.2.3. Growth Strategies

                16.2.2.4. SWOT Analysis

            16.2.3. ZIM Laboratories Limited

                16.2.3.1. Company Overview

                16.2.3.2. Company Financials

                16.2.3.3. Growth Strategies

                16.2.3.4. SWOT Analysis

            16.2.4. Access Pharmaceutical, Inc.

                16.2.4.1. Company Overview

                16.2.4.2. Company Financials

                16.2.4.3. Growth Strategies

                16.2.4.4. SWOT Analysis 

            16.2.5. C.L Pharm

                16.2.5.1. Company Overview

                16.2.5.2. Company Financials

                16.2.5.3. Growth Strategies

                16.2.5.4. SWOT Analysis

            16.2.6. Seoul Pharmaceuticals

                16.2.6.1. Company Overview

                16.2.6.2. Company Financials

                16.2.6.3. Growth Strategies

                16.2.6.4. SWOT Analysis

            16.2.7. Cure Pharmaceutical

                16.2.7.1. Company Overview

                16.2.7.2. Company Financials

                16.2.7.3. Growth Strategies

                16.2.7.4. SWOT Analysis

            16.2.8. Aquestive Therapeutics, Inc.

                16.2.8.1. Company Overview

                16.2.8.2. Company Financials

                16.2.8.3. Growth Strategies

                16.2.8.4. SWOT Analysis

            16.2.9. Solvay S.A.

                16.2.9.1. Company Overview

                16.2.9.2. Company Financials

                16.2.9.3. Growth Strategies

                16.2.9.4. SWOT Analysis

            16.2.10. NAL Pharma

                16.2.10.1. Company Overview

                16.2.10.2. Company Financials

                16.2.10.3. Growth Strategies

                16.2.10.4. SWOT Analysis

            16.2.11. IntelGenx Corp.

                16.2.11.1. Company Overview

                16.2.11.2. Company Financials

                16.2.11.3. Growth Strategies

                16.2.11.4. SWOT Analysis

            16.2.12. Izun Pharmaceuticals

                16.2.12.1. Company Overview

                16.2.12.2. Company Financials

                16.2.12.3. Growth Strategies

                16.2.12.4. SWOT Analysis

            16.2.13. Eisai Co., Ltd

                16.2.13.1. Company Overview

                16.2.13.2. Company Financials

                16.2.13.3. Growth Strategies

                16.2.13.4. SWOT Analysis

            16.2.14. AstraZeneca

                16.2.14.1. Company Overview

                16.2.14.2. Company Financials

                16.2.14.3. Growth Strategies

                16.2.14.4. SWOT Analysis

            16.2.15. Otsuka Pharmaceutical Co., Ltd.

                16.2.15.1. Company Overview

                16.2.15.2. Company Financials

                16.2.15.3. Growth Strategies

                16.2.15.4. SWOT Analysis

            16.2.16. Pfizer, Inc.

                16.2.16.1. Company Overview

                16.2.16.2. Company Financials

                16.2.16.3. Growth Strategies

                16.2.16.4. SWOT Analysis

            16.2.17. Teva Pharmaceutical Industries Ltd.

                16.2.17.1. Company Overview

                16.2.17.2. Company Financials

                16.2.17.3. Growth Strategies

                16.2.17.4. SWOT Analysis

            16.2.18. GlaxoSmithKline plc

                16.2.18.1. Company Overview

                16.2.18.2. Company Financials

                16.2.18.3. Growth Strategies

                16.2.18.4. SWOT Analysis

            16.2.19. Mylan N.V.

                16.2.19.1. Company Overview

                16.2.19.2. Company Financials

                16.2.19.3. Growth Strategies

                16.2.19.4. SWOT Analysis

            16.2.20. Bristol-Myers Squibb Company

                16.2.20.1. Company Overview

                16.2.20.2. Company Financials

                16.2.20.3. Growth Strategies

                16.2.20.4. SWOT Analysis

    List of Tables

    Table 01: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 02: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031

    Table 03: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031

    Table 04: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031

    Table 05: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 06: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 07: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 08: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 09: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 10: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031

    Table 11: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031

    Table 12: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031

    Table 13: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 14: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 15: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 16: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 17: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031

    Table 18: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031

    Table 19: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031

    Table 20: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 21: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 22: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 23: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 24: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031

    Table 25: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031

    Table 26: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031

    Table 27: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 28: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 29: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 30: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 31: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031

    Table 32: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031

    Table 33: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031

    Table 34: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 35: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 36: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 37: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 38: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031

    Table 39: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031

    Table 40: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031

    Table 41: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 42: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    List of Figures

    Figure 01: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Oral Transmucosal Drugs Market Value Share Analysis, by Type, 2020 and 2031

    Figure 03: Global Oral Transmucosal Drugs Market Attractiveness Analysis, by Type, 2021–2031

    Figure 04: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Tablets, 2017?2031

    Figure 05: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Buccal Films, 2017?2031

    Figure 06: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Liquid & Spray, 2017?2031

    Figure 07: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Gels, 2017?2031

    Figure 08: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Others, 2017?2031

    Figure 09: Global Oral Transmucosal Drugs Market Value Share Analysis, by Route of Penetration, 2020 and 2031

    Figure 10: Global Oral Transmucosal Drugs Market Attractiveness Analysis, by Route of Penetration, 2021–2031

    Figure 11: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Sublingual Mucosa, 2017–2031

    Figure 12: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Buccal Mucosa, 2017–2031

    Figure 13: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Gingival Tissues, 2017–2031

    Figure 14: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Palatal Tissues, 2017–2031

    Figure 15: Global Oral Transmucosal Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 16: Global Oral Transmucosal Drugs Market Attractiveness Analysis, by Distribution Channel, 2021–2031

    Figure 17: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Hospital Pharmacies, 2017?2031

    Figure 18: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Retail Pharmacies, 2017?2031

    Figure 19: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Online Pharmacies, 2017?2031

    Figure 20: Global Oral Transmucosal Drugs Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 21: Global Oral Transmucosal Drugs Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 22: Global Oral Transmucosal Drugs Market Value (US$ Mn), Cardiovascular Disorders, 2017–2031

    Figure 23: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Acute Pain Management, 2017–2031

    Figure 24: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Sedation, 2017–2031

    Figure 25: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Erectile Dysfunction, 2017–2031

    Figure 26: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Diabetes, 2017–2031

    Figure 27: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Others, 2017–2031

    Figure 28: Global Oral Transmucosal Drugs Market Value Share Analysis, by Region, 2020 and 2031

    Figure 29: Global Oral Transmucosal Drugs Market Attractiveness Analysis, by Region, 2021–2031

    Figure 30: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 31: North America Oral Transmucosal Drugs Market Value Share, by Country, 2020 and 2031

    Figure 32: North America Oral Transmucosal Drugs Market Attractiveness Analysis, by Country, 2021–2031

    Figure 33: North America Oral Transmucosal Drugs Market Value Share Analysis, by Type, 2020 and 2031

    Figure 34: North America Oral Transmucosal Drugs Market Attractiveness Analysis, by Type, 2021–2031

    Figure 35: North America Oral Transmucosal Drugs Market Value Share Analysis, by Route of Penetration, 2020 and 2031

    Figure 36: North America Oral Transmucosal Drugs Market Attractiveness Analysis, by Route of Penetration, 2021–2031

    Figure 37: North America Oral Transmucosal Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 38: North America Oral Transmucosal Drugs Market Attractiveness Analysis, by Distribution Channel, 2021–2031

    Figure 39: North America Oral Transmucosal Drugs Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 40: North America Oral Transmucosal Drugs Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 41: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 42: Europe Oral Transmucosal Drugs Market Value Share, by Country/Sub-region, 2020 and 2031

    Figure 43: Europe Oral Transmucosal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 44: Europe Oral Transmucosal Drugs Market Value Share Analysis, by Type, 2020 and 2031

    Figure 45: Europe Oral Transmucosal Drugs Market Attractiveness Analysis, by Type, 2021–2031

    Figure 46: Europe Oral Transmucosal Drugs Market Value Share Analysis, by Route of Penetration, 2020 and 2031

    Figure 47: Europe Oral Transmucosal Drugs Market Attractiveness Analysis, by Route of Penetration, 2021–2031

    Figure 48: Europe Oral Transmucosal Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 49: Europe Oral Transmucosal Drugs Market Attractiveness Analysis, by Distribution Channel, 2021–2031

    Figure 50: Europe Oral Transmucosal Drugs Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 51: Europe Oral Transmucosal Drugs Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 52: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 53: Asia Pacific Oral Transmucosal Drugs Market Value Share, by Country/Sub-region, 2020 and 2031

    Figure 54: Asia Pacific Oral Transmucosal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 55: Asia Pacific Oral Transmucosal Drugs Market Value Share Analysis, by Type, 2020 and 2031

    Figure 56: Asia Pacific Oral Transmucosal Drugs Market Attractiveness Analysis, by Type, 2021–2031

    Figure 57: Asia Pacific Oral Transmucosal Drugs Market Value Share Analysis, by Route of Penetration, 2020 and 2031

    Figure 58: Asia Pacific Oral Transmucosal Drugs Market Attractiveness Analysis, by Route of Penetration, 2021–2031

    Figure 59: Asia Pacific Oral Transmucosal Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 60: Asia Pacific Oral Transmucosal Drugs Market Attractiveness Analysis, by Distribution Channel, 2021–2031

    Figure 61: Asia Pacific Oral Transmucosal Drugs Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 62: Asia Pacific Oral Transmucosal Drugs Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 63: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 64: Latin America Oral Transmucosal Drugs Market Value Share, by Country/Sub-region, 2020 and 2031

    Figure 65: Latin America Oral Transmucosal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 66: Latin America Oral Transmucosal Drugs Market Value Share Analysis, by Type, 2020 and 2031

    Figure 67: Latin America Oral Transmucosal Drugs Market Attractiveness Analysis, by Type, 2021–2031

    Figure 68: Latin America Oral Transmucosal Drugs Market Value Share Analysis, by Route of Penetration, 2020 and 2031

    Figure 69: Latin America Oral Transmucosal Drugs Market Attractiveness Analysis, by Route of Penetration, 2021–2031

    Figure 70: Latin America Oral Transmucosal Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 71: Latin America Oral Transmucosal Drugs Market Attractiveness Analysis, by Distribution Channel, 2021–2031

    Figure 72: Latin America Oral Transmucosal Drugs Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 73: Latin America Oral Transmucosal Drugs Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 74: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 75: Middle East & Africa Oral Transmucosal Drugs Market Value Share, by Country/Sub-region, 2020 and 2031

    Figure 76: Middle East & Africa Oral Transmucosal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 77: Middle East & Africa Oral Transmucosal Drugs Market Value Share Analysis, by Type, 2020 and 2031

    Figure 78: Middle East & Africa Oral Transmucosal Drugs Market Attractiveness Analysis, by Type, 2021–2031

    Figure 79: Middle East & Africa Oral Transmucosal Drugs Market Value Share Analysis, by Route of Penetration, 2020 and 2031

    Figure 80: Middle East & Africa Oral Transmucosal Drugs Market Attractiveness Analysis, by Route of Penetration, 2021–2031

    Figure 81: Middle East & Africa Oral Transmucosal Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 82: Middle East & Africa Oral Transmucosal Drugs Market Attractiveness Analysis, by Distribution Channel, 2021–2031

    Figure 83: Middle East & Africa Oral Transmucosal Drugs Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 84: Middle East & Africa Oral Transmucosal Drugs Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 85: Position Analysis, 2020, by Tier and Size of the Company

Copyright © Transparency Market Research, Inc. All Rights reserved